RxDoctor Payments Data

Angela Craig, NP

Psychiatric/Mental Health · Deridder, LANPI 1902288095

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $634, 2.7 times the $235 reported in 2021.

$1,958in general payments, 2019–2025

Across 93 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$325
  • Johnson & Johnson$304
  • Alkermes, Inc.$270
  • Teva Pharmaceuticals USA, Inc.$203
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$185
  • Axsome Therapeutics, Inc.$135
  • plus $537 from 11 others

What the payments were for

  • Food & beverage$1,84794%
  • Education$1116%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,958 in reported general payments places this provider in the 60th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana →

Medicare billing

Part B allowed, 2024
$145,772
Medicare patients
223
Services billed
1,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole24$38,662
AuvelityDextromethorphan Hbr/Bupropion14$20,385
Risperdal ConstaRisperidone Microspheres13$15,720
BelsomraSuvorexant27$11,848
VyvanseLisdexamfetamine Dimesylate15$5,673
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$4,223
Duloxetine Hcl51$948
Divalproex Sodium ErDivalproex Sodium29$758
Quetiapine Fumarate73$701
Ziprasidone Hcl32$684
Aripiprazole18$667
Quetiapine Fumarate ErQuetiapine Fumarate22$600
Gabapentin34$512
Escitalopram Oxalate28$332
Benztropine Mesylate35$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$66$38,66224 claims
Axsome Therapeutics, Inc.Auvelity$135$20,38514 claims
Johnson & JohnsonRisperdal Consta$304$15,72013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Deridder

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →